ASX Share rice
Tue 18 May 2021 - 11:56:am (Sydney)

MX1 Share Price

MICRO-X LIMITEDMX1Health Care Equipment & Services

MX1 Company Information

Name:

Micro-X Limited

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Health Care Equipment & Supplies

GIC Sub Industry:

Health Care Equipment

Address:

A14 6 MAB Eastern Promenade Tonsley SA Australia 5042

Phone:

61 8 7099 3966

MD, CEO & Director:

Mr. Peter Robin Rowland

CFO & Company Sec.:

Mr. Kingsley Hall BEC

Chief Scientist:

Mr. Brian Gonzales

Bus. & Operations Mang.:

Mr. Dan Ginsburg

Gen. Counsel:

Ms. Bree Farrugia

Company Overview:

Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The company offers Carestream DRX Revolution Nano, an ultra-lightweight digital mobile X-ray system for bedside imaging for use in hospital wards and intensive care units; and Rover, a digital mobile X-Ray unit for deployed military hospitals. It is also developing Mobile Backscatter Imager for stand-off imaging of improvised explosive devices. The company was founded in 2011 and is based in Tonsley, Australia.

MX1 Share Price Information

Shares Issued:

459.70M

Market Capitalisation:

$158.60M

Revenue (TTM):

$5.84M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.066

Profit Margin:

-1.8313

Operating Margin (TTM):

$-2.18

Return On Assets (TTM):

$-0.30

Return On Equity (TTM):

$-1.21

Quarterly Revenue Growth (YOY):

1.896

Gross Profit(TTM):

$-1,763,000

Diluted Earnings Per Share (TTM):

$-0.033

MX1 CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-2,199,000

Change To Liabilities:

$411K

Total Cashflow From Investing Activities:

$-2,199,000

Net Borrowings:

$-916,000

Net Income:

$-10,067,000

Total Cash From Operating Activities:

$-9,456,000

Depreciation:

$1.25M

Change To Inventory:

$-543,000

Change To Account Receivables:

$-1,852,000

Sale Purchase Of Stock:

$31.50M

Capital Expenditures:

$2.13M

MX1 Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-10,067,000

Net Income:

$-10,067,000

Gross Profit:

$4M

Operating Income:

$-9,211,000

Other Operating Expenses:

$884K

Interest Expense:

$856K

Total Revenue:

$7.56M

Cost Of Revenue:

$3.55M

MX1 Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$1.04M

Total Liabilities:

$18.80M

Total Stockholder Equity:

$14.90M

Other Current Liabilities:

$3.01M

Total Assets:

$33.70M

Common Stock:

$84.30M

Other Current Assets:

$73K

Retained Earnings:

$-69,977,000

Other Liabilities:

$1.07M

Other Assets:

$840K

Cash:

$18.32M

Total Current Liabilities:

$8.75M

Property - Plant & Equipment:

$7.26M

Net Tangible Assets:

$14.71M

Total Current Assets:

$25.40M

Long-Term Debt:

$5.53M

Net Receivables:

$5.20M

Short-Term Investments:

$8.30M

Inventory:

$1.82M

Accounts Payable:

$1.54M

Short-Term Investments:

$8.30

Non Current Liabilities Total:

$10.05M

MX1 Share Price History

MX1 News

03 May, 2021
The big shareholder groups in Micro-X Limited ( ASX:MX1 ) have power over the company. Institutions will often hold...
02 Mar, 2021
Posts Revenue Growth of 32% And Adjusted EBITDA Growth of 53% Recurring Revenue Grows to 75% of Total Revenue CINCINNATI, March 02, 2021 (GLOBE NEWSWIRE) -- Protech Home Medical Corp. (the “Company”) (TSXV:PTQ; OTCQX:PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced its first quarter fiscal 2021 financial results and operational highlights. These results pertain to the three-month period ended December 31, 2020 and are reported in U.S. Dollars. Protech will host its Quarterly Earnings Conference Call on Tuesday, March 2, 2021 at 10:00 a.m. (EST). The dial-in number is 1 (800) 319-4610 or 1 (604) 638-5340. Financial Highlights: Revenue for Q1 2021 was $22.8 million compared to $17.2 million for Q1 2020, representing a 32% increase in revenue year-over-year. Compared to Q4, 2020, the Company experienced strong organic growth of 5%.Average Recurring Revenue for trailing twelve month at the end of Q1 2021 represents 75% of total revenue.Adjusted EBITDA for Q1 2021 was $5.1 million (22.5% margin), compared to Adjusted EBITDA for Q1 2020 of $3.3 million (19.4% margin), representing a 53% increase year-over-year.Operating Expense for Q1 2021 was 50.7 %, compared to Q1 2020 of 56.2 %, a substantial margin improvement resulting from scaling on our existing platformCash flow from continuing operations was $2.8 million in Q1 2021 compared to $3.6 million in Q1 2020, the variance was primarily due to changes in working capital.The Company reported $23.6 million of cash on hand as at December 31, 2020 compared to $6.4 million at December 31, 2019 in addition to having an undrawn credit facility of $20 million as at December 31, 2020. Operational Highlights: Through the Company’s continued use of technology and centralized intake processes, respiratory resupply set-ups and/or deliveries increased to 34,996 for Q1 2021, compared to 13,439 for Q1 2020, an increase of 160%.The Company’s customer base increased 33% year over year to 51,836 unique patients served in Q1 2021 from 39,070 unique patients in Q1 2020.Compared to 62,999 unique set-ups/deliveries in Q1 2020, the Company completed 76,691 unique set-ups/deliveries in Q1 2021, an increase of 22%.The Company continues to experience robust demand for respiratory equipment, such as oxygen concentrators, ventilators, as well as the CPAP resupply and other supplies business. Subsequent Events to the three months ended December 31, 2020: On January 13th the Company announced it has applied to list its common shares on the NASDAQ Capital Market (“NASDAQ”). Subject to meeting all conditions to listings, the Company is targeting completion within the 1st half of 2021. On February 2nd the Company announced the acquisition of Mayhugh’s Medical Equipment (“MME”), a respiratory care company based in Florida, reporting unaudited trailing 12-month annual revenues of approximately $5.5 million and Adjusted EBITDA of approximately $946,000. MME adds over 10,000 active patients to Protech’s patient population and represents Protech’s 49th location and entrance into its 11th U.S. State. Management Commentary: “The momentum across the business continues to be robust as evidenced by our first quarter financial and operating results, and I am pleased to say that we are seeing similar strong trends into our second quarter,” said CEO and Chairman Greg Crawford. “Over the last few years, we have applied financial resources and operating expertise to build an unparalleled scalable platform which is poised for tremendous growth. We have the ability to leverage this patient centric platform to make sizeable acquisitions in new and existing markets and integrate them with ease. Coupling this with our significant financial resources, we have never been more excited as to what we can accomplish as a company and have our eyes set on transforming into a national provider of respiratory home care in the United States. As seen in our financials, our recurring revenue grew to 75% of total revenue and we anticipate a further uptick with a full quarter of contribution from SleepWell. This strong recurring revenue platform provides us further stability and consistency as it relates to our growth outlook and is a direct result of the infrastructure we have developed. Our path forward is crystal clear, and with an extremely healthy balance sheet our focus for 2021 is to seek larger, more transformative acquisitions. Lastly, I’d like to thank the entire Protech team for their tireless efforts and stakeholders for all of their continued support.” Chief Financial Officer Hardik Mehta added, “We are extremely pleased to have transitioned to reporting in U.S. dollars, representing an important step forward in our goal to simplify our reporting and capital markets presentation for investors. We are excited to see the sustained margin acceleration and strong recurring revenue growth that we experienced in the first quarter. Our Adjusted EBITDA margin remains strong as we continue to experience tailwinds across the Company. We also expect our results to further improve as our sleep business normalizes and exceeds historical levels as we move through 2021. On the acquisition front, we are looking forward to quickly scaling up in Florida on the heels of closing MME, and have a full pipeline of acquisition targets in current and new markets that we will continue to assess in the coming months.” The financial statements of the Company for the three months ended December 31, 2020 and 2019 and accompanying Management Discussion & Analysis (MD&A) are available at www.sedar.com. ABOUT PROTECH HOME MEDICAL CORP. The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient. Forward-Looking Statements Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, including: the Company’s acquisition plans; the Company listing on NASDAQ; the Company expecting its results to further improve and exceed historical levels through 2021; are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the Company’s ability to maintain/slightly increase its collections ratios; the Company maintaining its gross margins and maintaining its revenue growth; and the Company maintaining its selling, general and administrative expenses; the Company obtaining all necessary approvals to list on NASDAQ; and the Company successfully identified, negotiating and completing additional acquisitions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: credit; market (including equity, commodity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the U.S.; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; and the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Non-GAAP Measures This press release refers to “Adjusted EBITDA” which is a non-GAAP and non-IFRS financial measure that does not have a standardized meaning prescribed by GAAP or IFRS. The Company’s presentation of this financial measure may not be comparable to similarly titled measures used by other companies. This financial measure is intended to provide additional information to investors concerning the Company’s performance. Adjusted EBITDA is defined as EBITDA excluding stock-based compensation. Adjusted EBITDA is a Non-IFRS measure the Company uses as an indicator of financial health and excludes several items which may be useful in the consideration of the financial condition of the Company, including interest expense, income taxes, depreciation, amortization, stock-based compensation, goodwill impairment and change in fair value of debentures and financial derivatives. The following table shows our Non-IFRS measure (Adjusted EBITDA) reconciled to our net income for the indicated periods: Three Months EndedDec 31, 2020 Three Months EndedDec 31, 2019 Net income (loss) from continuing operations$229 $(1,328) Add back: Depreciation and amortization 3,304 3,629 Interest expense (net of interest income) 487 457 Change in fair value of financial derivative liabilities 1,091 553 EBITDA $ 5,111 $ 3,311 Stock-based compensation 15 32 Adjusted EBITDA $ 5,126 $ 3,343 % of Net Revenue 22.5% 19.4% Management uses this non-IFRS measure as a key metric in the evaluation of the Company’s performance and the consolidated financial results. The Company believes this non-IFRS measure is useful to investors in their assessment of the operating performance and the valuation of the Company. In addition, this non-IFRS measure addresses questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors. However, non-IFRS financial measures are not prepared in accordance with IFRS, and the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with IFRS. The listing of the Company’s common shares on the NASDAQ remains subject to the approval of the listing application by NASDAQ and the satisfaction of all applicable listing and regulatory requirements, as well as effectiveness of the registration statement with the United States Securities and Exchange Commission. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information please visit our website at www.protechhomemedical.com, or contact: Cole StevensVP of Corporate DevelopmentProtech Home Medical Corp.859-300-6455cole.stevens@myphm.com Gregory CrawfordChief Executive OfficerProtech Home Medical Corp.859-300-6455investorinfo@myphm.com
22 Feb, 2021
Company to Report Financial Results in U.S. Dollars Going ForwardCINCINNATI, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Protech Home Medical Corp. (the “Company”) (TSXV:PTQ; OTCQX:PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced that it will host its Q1 Fiscal 2021 earnings conference call and audio webcast on Tuesday, March 2, 2021 at 10:00 a.m. (EST). Conference Call Details: Tuesday, March 2, 2021 at 10:00 a.m. (EST). Canada/US Toll Free: 1 (800) 319 4610International: 1 (604) 638 5340 Audio Webcast Details: The live audio webcast can be found on the investor section of the Company’s website through the following link:https://protechhomemedical.com/conference_calls “As we work towards completion of our planned NASDAQ listing, and execute on our comprehensive capital markets strategy for 2021 and beyond, we have decided Q1 Fiscal 2021 is the optimal time to begin reporting our financial results in U.S. dollars. This change will allow our investors to make constant currency comparisons on a go forward basis, thus removing the FX impact from our financial reporting,” said Greg Crawford, Chairman and CEO of Protech. “We are delighted to make this important change to our financial reporting presentation, completing another milestone in our company’s evolution. As a whole we have grown into a significant regional respiratory care provider in the United States and are knocking on the door of becoming a national provider, as we leverage our significant infrastructure and seek to add turn-key respiratory home care operators to our family of companies. We have an exceptional pipeline of potential acquisition targets, which we expect to keep us very busy over the months to come.” The listing of the Company’s common shares on the NASDAQ Capital Market (“NASDAQ”) remains subject to the approval of ‎the listing application by NASDAQ and the satisfaction of all applicable listing and regulatory ‎requirements, as well as effectiveness of the registration statement with the United States Securities and Exchange Commission (the “SEC”).‎ ABOUT PROTECH HOME MEDICAL The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient. Forward-Looking Statements Certain statements contained in this press release constitute "forward-looking information" as such term is ‎‎‎‎defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", ‎‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate ‎‎‎‎to the Company, including: the potential listing of Protech’s common shares on NASDA‎Q and its plans to file a Registration Statement with the SEC; and Protech expecting to be very busy with acquisitions over the months to come; are intended to identify ‎forward-looking information. All ‎statements other than ‎statements of ‎historical fact may be forward-looking ‎information. Such statements reflect the ‎Company's current ‎views and ‎intentions with respect to future events, and ‎current information available to the ‎Company, and are ‎subject to ‎certain risks, uncertainties and assumptions, including: failure to get the necessary approval to list on Nasdaq; and the Company ‎successfully identified, negotiating and completing additional acquisitions, including accretive acquisitions. ‎Many factors ‎could ‎cause the actual results, performance or achievements that may be expressed or ‎implied by ‎such forward-‎looking ‎information to vary from those described herein should one or more of these risks ‎or ‎uncertainties ‎materialize. ‎Examples of such risk factors include, without limitation: credit; market (including ‎‎equity, commodity, ‎foreign ‎exchange and interest rate); liquidity; operational (including technology and ‎‎infrastructure); ‎reputational; ‎insurance; strategic; regulatory; legal; environmental; capital adequacy; the ‎‎general business and ‎economic ‎conditions in the regions in which the Company operates; the ability of the ‎‎Company to execute on key ‎priorities, ‎including the successful completion of acquisitions, business retention, and ‎‎strategic plans and to ‎attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; ‎‎the ability to ‎implement business ‎strategies and pursue business opportunities; low profit market segments; ‎‎disruptions in or ‎attacks (including ‎cyber-attacks) on the Company's information technology, internet, network ‎‎access or other ‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎‎criminal ‎behavior to which ‎the Company is exposed; the failure of third parties to comply with their obligations to ‎‎the ‎Company or its ‎affiliates; the impact of new and changes to, or application of, current laws and regulations; ‎‎‎decline of ‎reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; ‎‎‎‎dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult ‎‎‎‎litigation environment, including in the U.S.; increased competition; changes in foreign currency rates; increased ‎‎‎‎funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds ‎‎‎‎and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, ‎‎‎‎and methods used by the Company; the occurrence of natural and unnatural catastrophic events ‎and claims ‎‎‎‎resulting from such events; and risks related to COVID-19 including various recommendations, orders ‎and ‎‎‎measures of governmental ‎authorities ‎to try to limit the pandemic, including travel restrictions, border closures, ‎‎‎‎non-essential business ‎closures, ‎quarantines, self-isolations, shelters-in-place and social distancing, disruptions ‎‎‎to ‎markets, economic ‎activity, ‎financing, supply chains and sales channels, and a deterioration of general ‎‎‎economic ‎conditions ‎including a ‎possible national or global recession‎; as well as those risk factors discussed or ‎‎‎referred to in ‎the Company’s disclosure ‎documents filed with the securities regulatory authorities in certain ‎‎‎provinces of Canada ‎and available at ‎www.sedar.com. Should any factor affect the Company in an unexpected ‎‎‎manner, or should ‎assumptions ‎underlying the forward-looking information prove incorrect, the actual results or ‎‎‎events may differ ‎materially ‎from the results or events predicted. Any such forward-looking information is ‎‎‎expressly qualified in its ‎entirety by ‎this cautionary statement. Moreover, the Company does not assume ‎‎‎responsibility for the accuracy or ‎‎completeness of such forward-looking information. The forward-looking ‎‎‎information included in this press release ‎is ‎made as of the date of this press release and the Company undertakes ‎‎‎no obligation to publicly update or revise ‎any ‎forward-looking information, other than as required by applicable ‎‎‎law.‎‎ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of ‎‎the ‎TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.‎ For further information please visit our website at www.protechhomemedical.com, or contact:‎ Cole StevensVP of Corporate Development ‎Protech Home Medical Corp.‎‎859-300-6455‎cole.stevens@myphm.com Gregory CrawfordChief Executive OfficerProtech Home Medical Corp.‎‎859-300-6455‎investorinfo@myphm.com
10 Feb, 2021
Webcasted Presentation to Be Held Tuesday, February 16, 2021 at 3:30PM (EST)CINCINNATI, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Protech Home Medical Corp. (the “Company” or “Protech”) (TSXV:PTQ; OTCQX:PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced that it will be presenting at The MicroCap Rodeo Winter Wonderland Conference on February 16, 2021 at 3:30pm (EST). Greg Crawford, CEO of Protech, will be presenting to a live, virtual audience. Webcasted Presentation Event:MicroCap Rodeo Winter WonderlandDate:Tuesday, February 16, 2021Time:3:30pm (EST) The live webcast of the Company’s presentation will be available by visiting the investors' section of the Company's website at www.protechhomemedical.com. The webcast will also be available for replay on the Company's website following the event. ABOUT THE MICROCAP RODEO WINTER WONDERLAND CONFERENCE The MicroCap Rodeo Winter Wonderland Conference is a virtual conference showcasing 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented as one of their best ideas. ABOUT PROTECH HOME MEDICAL The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient. Forward-Looking Statements Certain statements contained in this press release constitute "forward-looking information" as such term is ‎‎‎defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", ‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate ‎‎‎to the Company, including the Company presenting at the event and posting material on its website, are intended to identify ‎forward-looking information. All statements other than ‎statements of ‎historical fact may be forward-looking ‎information. Such statements reflect the Company's current ‎views and ‎intentions with respect to future events, and ‎current information available to the Company, and are ‎subject to ‎certain risks, uncertainties and assumptions. Many factors ‎could ‎cause the actual results, performance or achievements that may be expressed or ‎implied by such forward-‎looking ‎information to vary from those described herein should one or more of these risks ‎or uncertainties ‎materialize. ‎Examples of such risk factors include, without limitation: credit; market (including ‎equity, commodity, ‎foreign ‎exchange and interest rate); liquidity; operational (including technology and ‎infrastructure); ‎reputational; ‎insurance; strategic; regulatory; legal; environmental; capital adequacy; the ‎general business and ‎economic ‎conditions in the regions in which the Company operates; the ability of the ‎Company to execute on key ‎priorities, ‎including the successful completion of acquisitions, business retention, and ‎strategic plans and to ‎attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; ‎the ability to ‎implement business ‎strategies and pursue business opportunities; low profit market segments; ‎disruptions in or ‎attacks (including ‎cyber-attacks) on the Company's information technology, internet, network ‎access or other ‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎criminal ‎behavior to which ‎the Company is exposed; the failure of third parties to comply with their obligations to ‎the ‎Company or its ‎affiliates; the impact of new and changes to, or application of, current laws and regulations; ‎‎decline of ‎reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; ‎‎‎dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult ‎‎‎litigation environment, including in the U.S.; increased competition; changes in foreign currency rates; increased ‎‎‎funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds ‎‎‎and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, ‎‎‎and methods used by the Company; the occurrence of natural and unnatural catastrophic events ‎and claims ‎‎‎resulting from such events; and risks related to COVID-19 including various recommendations, orders ‎and ‎‎measures of governmental ‎authorities ‎to try to limit the pandemic, including travel restrictions, border closures, ‎‎‎non-essential business ‎closures, ‎quarantines, self-isolations, shelters-in-place and social distancing, disruptions ‎‎to ‎markets, economic ‎activity, ‎financing, supply chains and sales channels, and a deterioration of general ‎‎economic ‎conditions ‎including a ‎possible national or global recession‎; as well as those risk factors discussed or ‎‎referred to in ‎the Company’s disclosure ‎documents filed with the securities regulatory authorities in certain ‎‎provinces of Canada ‎and available at ‎www.sedar.com. Should any factor affect the Company in an unexpected ‎‎manner, or should ‎assumptions ‎underlying the forward-looking information prove incorrect, the actual results or ‎‎events may differ ‎materially ‎from the results or events predicted. Any such forward-looking information is ‎‎expressly qualified in its ‎entirety by ‎this cautionary statement. Moreover, the Company does not assume ‎‎responsibility for the accuracy or ‎‎completeness of such forward-looking information. The forward-looking ‎‎information included in this press release ‎is ‎made as of the date of this press release and the Company undertakes ‎‎no obligation to publicly update or revise ‎any ‎forward-looking information, other than as required by applicable ‎‎law.‎‎ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of ‎the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.‎ For further information please visit our website at www.protechhomemedical.com, or contact: Cole StevensVP of Corporate Development Protech Home Medical Corp.859-300-6455cole.stevens@myphm.com Gregory CrawfordChief Executive OfficerProtech Home Medical Corp.859-300-6455investorinfo@myphm.com
05 Jan, 2021
Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...
29 Nov, 2020
We feel now is a pretty good time to analyse Micro-X Limited's (ASX:MX1) business as it appears the company may be on...